Meso Foundation Funds Updated NCCN Resources for Mesothelioma Patients

Through partial funding by the Mesothelioma Applied Research Foundation, the National Comprehensive Cancer Network (NCCN) has published updated patient resources for malignant pleural mesothelioma. The resources include the NCCN Guidelines for Patients and NCCN Quick Guide sheet.
The NCCN Guidelines for Patients is based on the guidelines used globally in clinical practice to allow health care […]

How One Meso Foundation Board Member Helps Advance Field at IASLC Conference

Melissa Culligan, a member of the Mesothelioma Applied Research Foundation’s Board of Directors started her work on Saturday, December 3 at the 17th World Conference on Lung Cancer (WCLC), held in Vienna, Austria by attending an all day working meeting focused on the development of an Immunotherapy Guideline for clinicians. This working meeting was held […]

Update from World Conference on Lung Cancer 2016 (Mesothelioma Track) – Day 2

Results from studies using PDL1 inhibitors
Today, at the World Conference on Lung Cancer 2016 (Mesothelioma Track), several investigators presented data for their immunotherapy studies. The first three presentations focused on PDL1 inhibitors.
Dr. Paul Baas began the session by presenting data from his Phase II study of nivolumab, an immunotherapy agent. Though his study showed no […]

Mesothelioma Interest Growing

“Mesothelioma is known as a traditionally under-funded and under-studied cancer.”
That’s the answer customarily given to patients, their families, and the public at large when they ask about the very slow advances that were so typical of mesothelioma. Until now.
And while technically that is still true, especially when compared to other cancers, some changes are […]